Literature DB >> 10600358

Increased risk of antibody-mediated rejection of reduced-size liver allografts.

I Astarcioglu1, R Cursio, M Reynes, J Gugenheim.   

Abstract

Because of the shortage of liver allografts in children, transplantation of reduced-size liver allografts from adult cadaveric donors or living, related donors is being done more frequently. Reduced-size liver allografts may be used in cases of ABO incompatibility and T-cell warm cross-match positivity. This experimental study in inbred rats was undertaken to determine if reduced-size liver allografts are more sensitive to antibody-mediated rejection than full-size liver allografts. Brown-Norway (BN) (RT1(n)) rats were sensitized by three successive skin grafts at 10-day intervals. Then orthotopic Lewis (LEW) (RT1(1)) liver grafts were transplanted into these BN rats. Full-size liver allografts were compared with reduced-size liver allografts (70% of donor liver). Control groups were composed of full-size and/or reduced-size isografts. Titers of specific antibodies were assayed using a complement-dependent assay before and after orthotopic liver transplantation. Histological and immunofluorescence studies (IgG, IgM, C(3), and fibrinogen deposits) were assessed. Recipients of reduced-size liver allografts died of hyperacute rejection at 36.6 +/- 4.1 h, significantly earlier than recipients receiving full-size liver allografts, which died of accelerated acute rejection at 259.2 +/- 25.2 h (P < 0.001). Either full-size or reduced-size isograft recipients survived indefinitely. A decrease in the titers of donor-specific antibodies was observed in both groups of animals. Slight deposits of IgG, IgM, C(3), and fibrinogen were observed in recipients of reduced-size liver allografts, whereas larger deposits were observed in recipients of full-size liver allografts. Our data demonstrate that there is an increased risk of antibody-mediated rejection of reduced-size liver allografts in sensitized recipients. This may have important clinical implications for partial liver grafting in cases of ABO incompatibility and T-cell warm cross-match positivity. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600358     DOI: 10.1006/jsre.1999.5734

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  3 in total

Review 1.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

2.  In vivo hypoxic preconditioning protects from warm liver ischemia-reperfusion injury through the adenosine A2B receptor.

Authors:  Alexander Choukèr; Akio Ohta; André Martignoni; Dmitriy Lukashev; Lefteris C Zacharia; Edwin K Jackson; Jürgen Schnermann; Jerrold M Ward; Ines Kaufmann; Brenda Klaunberg; Michail V Sitkovsky; Manfred Thiel
Journal:  Transplantation       Date:  2012-11-15       Impact factor: 4.939

3.  Acute Antibody-mediated Rejection Coexisting With T Cell-mediated Rejection in Pediatric ABO-incompatible Transplantation.

Authors:  Yusuke Yanagi; Seisuke Sakamoto; Masaki Yamada; Koutaro Mimori; Toshimasa Nakao; Tasuku Kodama; Hajime Uchida; Seiichi Shimizu; Akinari Fukuda; Noriyuki Nakano; Chiduko Haga; Takako Yoshioka; Mureo Kasahara
Journal:  Transplant Direct       Date:  2022-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.